| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 1 Aug 2025 | 24 Jul 2025 |
| Alivus Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2025 inter alia to consider and approve to consider and approve the Unaudited Financial Results for the quarter ended 30th June 2025. Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that the Board at its meeting held today approved the unaudited Financial Results for the First Quarter ended June 30, 2025. The said meeting of the Board commenced at 5.00 p.m. and concluded at 5.50 p.m. The copy of the said results, and Limited Review Report of the Auditor is enclosed herewith. These are also being made available on the website of the Company at www.alivus.com You are requested to take the same on record. (As Per BSE Announcement Dated on: 01/08/2025) | ||
| Board Meeting | 15 May 2025 | 8 May 2025 |
| Alivus Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2025 inter alia to consider and approve the Audited Financial Results of the Company for the quarter and year ended 31st March 2025 and to consider and recommend dividend if any on Equity shares for the year ended March 31 2025. Audited Financial Results for the Fourth Quarter and Year ended March 31, 2025 This is to inform you that the Board of Directors of the Company has at its meeting held today, recommended payment of Final Dividend for the Financial Year 2024-25 of Rs. 5/- (250%) per equity share of Rs. 2 each, subject to the approval of shareholders at the ensuing Annual General Meeting. Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulation, 2015 - Change in Directore of Alivus Life Sciences Limited. Please find attached hewith intimation with respect to Appointment of Secretarial Auditor (As Per BSE Announcement dated on 15.05.2025) | ||
| Board Meeting | 23 Jan 2025 | 16 Jan 2025 |
| Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2025 inter alia to consider and approve the Unaudited Financial Results of the Company for the third quarter and nine months ended 31st December 2024. We would wish to inform you that the Board at its meeting held today approved the Unaudited Financial Results for the Third Quarter and Nine months ended December 31, 2024. (As Per BSE Announcement Dated on: 23/01/2025) | ||
| Board Meeting | 24 Oct 2024 | 17 Oct 2024 |
| Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/10/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the second quarter and half year ended 30th September 2024. Please find attached herewith unaudited Finacial Results for the second quarter and half year ended 30th September 2024 (As per BSE Announcement Dated on 24/10/2024) | ||
The drug consists of a combination of dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate.
The Mumbai-based company's income from operations decreased by roughly 15% to ₹507 Crore in the three months ended September 30.
Here are some of the stocks that may see significant price movement today: ITC, Kansai Nerolac, Coromandel International, etc.
The sale will be conducted through the stock exchange mechanism, adhering to applicable legal requirements.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
